http://dspace.bsu.edu.ru/handle/123456789/31699
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Levkova, E. A. | - |
dc.contributor.author | Pazhinsky, A. L. | - |
dc.contributor.author | Bashuk, V. V. | - |
dc.contributor.author | Dubovtsova, E. Yu. | - |
dc.contributor.author | Dolzhikov, A. A. | - |
dc.contributor.author | Beskhmelnitsyna, E. A. | - |
dc.contributor.author | Vain, D. S. | - |
dc.contributor.author | Gureev, V. V. | - |
dc.date.accessioned | 2020-06-09T11:47:42Z | - |
dc.date.accessioned | 2020-06-09T11:47:43Z | - |
dc.date.available | 2020-06-09T11:47:42Z | - |
dc.date.available | 2020-06-09T11:47:43Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Retinoprotective effects of non-selective imidazoline receptor agonists / E.A. Levkova, A.L. Pazhinsky, V.V. Bashuk [et al.] // Journal of international pharmaceutical research. - 2019. - Vol.46, №4.-P. 209-214. | ru |
dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/31699 | - |
dc.description.abstract | Current drug therapy of ophtalmic diseases associated with retinal ischemia is not always successful enough that ensures the relevance of the search of new effective drugs | ru |
dc.language.iso | en | ru |
dc.subject | medicine | ru |
dc.subject | pharmacology | ru |
dc.subject | imidazoline receptor ligands | ru |
dc.subject | retinal ischemia-reperfusion model | ru |
dc.subject | rats | ru |
dc.subject | pharmacological correction | ru |
dc.title | Retinoprotective effects of non-selective imidazoline receptor agonists | ru |
dc.type | Article | ru |
Appears in Collections: | Статьи из периодических изданий и сборников (на иностранных языках) = Articles from periodicals and collections (in foreign languages) Статьи из периодических изданий и сборников (на иностранных языках) = Articles from periodicals and collections (in foreign languages) |
File | Description | Size | Format | |
---|---|---|---|---|
Levkova_Retinoprotective.pdf | 158.5 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.